GlassScriptPhysician profile
Paige A Hendrix
NPI 1295088409
$2,178.79
in general payments reported to CMS, 2019-2025
23 companies · $712 in 2025
The $712 reported for 2025 was more than what 92% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $94.48 · 2023: $632 · 2024: $592 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.56 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $349.75 | 2022-2025 | |
| Astellas Pharma US INC | $334.97 | 2023-2025 | Veozah, Cresemba |
| Abbvie INC. | $323.08 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.26 | 2021-2025 | |
| Medtronic, INC. | $137.18 | 2024 | Abre |
| Exeltis, USA INC. | $122.89 | 2023-2025 | Slynd |
| Exact Sciences Corporation | $119.67 | 2023-2025 | Cologuard Collection Kit |
| Coopersurgical, INC. | $98.23 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $86.86 | 2021-2025 | Coolseal Generator, Acessa Provu System, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $78.04 | 2025 | Myfembree, Gemtesa |
| Organon LLC | $71.89 | 2023-2025 | Nexplanon |
| Novo Nordisk INC | $54.11 | 2024-2025 | Wegovy |
| Sage Therapeutics, LLC | $48.65 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $45.85 | 2024-2025 | Gardasil 9, Gardasil |
| Pfizer INC. | $29.80 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Northgate Technologies, INC. | $19.86 | 2024 | Stimsite |
| Smith+Nephew, INC. | $19.85 | 2025 | Pico |
| Mimedx Group, INC. | $17.48 | 2025 | |
| Millicent US INC | $16.52 | 2025 | Intrarosa, Femring |
| Supernus Pharmaceuticals, INC. | $15.96 | 2025 | Qelbree |
| Shield Therapeutics INC | $15.77 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $14.56 | 2024 | Quviviq |
| Therapeuticsmd, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.